The National Eye Institute seeks research co-development partners and/or licensees for a therapy using an FDA-approved small molecule drug reserpine (and related compounds especially halofantrine) that prevents photoreceptor cell death in retinal degenerations.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for single-cell RNA sequencing (scRNA-seq) analysis software that leverages existing large language models (LLM) to simplify and enhance data analysis by providing intelligent recommendations and interpretations.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of RPGR gene therapy for Retinitis Pigmentosa.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a mini-bioreactor designed to enhance organoid culture outcomes.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a robust method to generate macular and peripheral retinal pigment epithelium (RPE) cells for targeted therapies and drug discovery.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a biodegradable tissue scaffold designed for multi-tissue transplantation.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative detection methods for organomercurial biosynthesis in microbial communities.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a targeted disruption of the Rpe65 gene in mice, a novel model for studying retinal diseases and testing potential therapies.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a novel shipping container designed to protect live cell cultures during transport.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative gene therapy for retinal diseases.